Breast cancer (invasive) · line 1 · TCHP — docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+ neoadjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-TCHP-NEOADJUVANT`

ID	`IND-BREAST-HER2-POS-EARLY-NEOADJUVANT`
Type	Indication
Status	pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ESMO-BREAST-EARLY-2024` `SRC-NCCN-BREAST-2025`

Notes

Stage II-III HER2+ standard. APHINITY trial supports adjuvant pertuzumab post-pCR in node-positive. KATHERINE pathway for residual disease — major iDFS gain.

Used By

Algorithms

ALGO-BREAST-1L - ALGO-BREAST-1L

Red flag

RF-BREAST-EARLY-STAGE - Early-stage (non-metastatic) breast cancer: clinical or pathological stage I, II, or III....